Last reviewed · How we verify

NCT05155813

Prevalence of Sleep Apnea and Atrial Fibrillation

Status unknown Last updated 7 June 2022
What this trial tests

trial testing WatchPAT in Sleep Apnea in 300 participants. Status unknown.

Timeline
1 February 2022
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date1 February 2022
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Sleep Apnea or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will screen consecutive patients presenting to the atrial fibrillation clinic for sleep apnea using a FDA-approved home sleep testing device, WatchPAT to determine prevalence of sleep apnea in a clinic-based sample.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of obstructive sleep apnea among consecutive patients with all patterns of atrial fibrillation using WatchPAT home sleep testing.
    Mills EW, Cassidy M, Sofer T, Tadros T, et al · · 2023 · cited 8× · PMID 37019195 · DOI 10.1016/j.ahj.2023.03.014

Verify or expand the search:

Other trials of WatchPAT

Trials testing the same drug.

Other recruiting trials for Sleep Apnea

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05155813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing